Ex-Dividend Reminder: GE HealthCare Technologies, Pfizer and Old Second Bancorp

GE HealthCare Technologies (GEHC), Pfizer (PFE), and Old Second Bancorp (OSBC) will trade ex-dividend on July 25, 2025, for their upcoming quarterly dividends. Investors should anticipate price adjustments reflecting these payouts: GEHC's $0.035 dividend implies a 0.05% price reduction, PFE's $0.43 dividend a 1.71% reduction, and OSBC's $0.06 dividend a 0.32% reduction, all else being equal. The estimated annualized yields for these companies are 0.18% for GEHC, 6.84% for PFE, and 1.29% for OSBC.

Analysis

GE HealthCare Technologies (GEHC), Pfizer (PFE), and Old Second Bancorp (OSBC) are scheduled to trade ex-dividend on July 25, 2025. The market is expected to price in these distributions accordingly, with PFE's stock anticipated to open approximately 1.71% lower, reflecting its substantial $0.43 quarterly dividend. In contrast, GEHC and OSBC will see much smaller adjustments of 0.05% and 0.32% for their respective dividends of $0.035 and $0.06. The key differentiator for income-focused investors is the vast disparity in annualized yields: Pfizer offers a significant 6.84%, while Old Second Bancorp provides a more modest 1.29% and GE HealthCare a nominal 0.18%. This suggests that Pfizer's capital return policy is a central part of its investment proposition, whereas for GEHC, the dividend is minimal. On the day of the report, all three equities traded higher, with PFE and GEHC showing notable gains of 3.6% and 3.1% respectively, indicating positive short-term market sentiment that may be unrelated to the standard dividend announcement.

Key Decisions for Investors

• Investors seeking to capture the upcoming dividend must own the shares before the July 25, 2025 ex-dividend date.
• For income-focused portfolios, Pfizer's 6.84% estimated annualized yield is the most compelling of the three, but investors should anticipate a corresponding 1.71% price drop on the ex-dividend date, all else being equal.
• Given GE HealthCare's minimal 0.18% yield, the investment case for GEHC should be predicated on growth or other fundamental factors rather than income generation.
• As the article notes that dividend predictability varies, it is prudent to review the historical dividend stability of each company, especially for Pfizer, to assess the likelihood of the high yield continuing.